Revenue Recognition and Accounts Receivable Revenue Disaggregation (Table) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025
Disaggregation of Revenue [Line Items]
Net sales	$ 3,734.7	$ 3,747.5	$ 10,990.3	$ 10,559.7
Brands
Disaggregation of Revenue [Line Items]
Net sales	2,461.4	2,436.8	7,212.3	6,838.2
Generics
Disaggregation of Revenue [Line Items]
Net sales	1,273.3	1,310.7	3,778.0	3,721.5
Lipitor
Disaggregation of Revenue [Line Items]
Net sales	451.9	396.1	1,366.1	1,172.0
Norvasc
Disaggregation of Revenue [Line Items]
Net sales	190.2	179.7	600.4	534.7
EpiPen® Auto-Injectors
Disaggregation of Revenue [Line Items]
Net sales	155.8	157.2	386.1	390.7
Lyrica ®
Disaggregation of Revenue [Line Items]
Net sales	114.2	126.5	355.4	367.2
Viagra ®
Disaggregation of Revenue [Line Items]
Net sales	94.1	105.2	302.0	304.0
Creon ®
Disaggregation of Revenue [Line Items]
Net sales	98.1	93.1	292.9	266.9
Celebrex ®
Disaggregation of Revenue [Line Items]
Net sales	70.2	73.3	213.7	206.7
Effexor ®
Disaggregation of Revenue [Line Items]
Net sales	63.9	67.2	192.6	189.6
Zoloft ®
Disaggregation of Revenue [Line Items]
Net sales	78.8	66.8	222.8	188.1
Xalabrands
Disaggregation of Revenue [Line Items]
Net sales	43.9	38.6	121.9	116.4
Influvac ®
Disaggregation of Revenue [Line Items]
Net sales	90.6	125.4	100.5	130.8
Yupelri ®
Disaggregation of Revenue [Line Items]
Net sales	71.5	71.4	204.7	196.3
Xanax ®
Disaggregation of Revenue [Line Items]
Net sales	36.6	34.2	109.5	100.4
Amitiza ®
Disaggregation of Revenue [Line Items]
Net sales	36.4	40.8	109.8	115.7
Dymista ®
Disaggregation of Revenue [Line Items]
Net sales	35.4	33.8	112.5	125.0
Developed Markets Segment \| Brands
Disaggregation of Revenue [Line Items]
Net sales	1,184.6	1,241.3	3,375.9	3,382.5
Developed Markets Segment \| Generics
Disaggregation of Revenue [Line Items]
Net sales	1,031.3	1,014.3	3,054.5	2,884.1
Greater China \| Brands
Disaggregation of Revenue [Line Items]
Net sales	697.1	612.3	2,085.1	1,751.6
Greater China \| Generics
Disaggregation of Revenue [Line Items]
Net sales	5.5	2.9	11.4	8.0
Japan, Australia and New Zealand Segment \| Brands
Disaggregation of Revenue [Line Items]
Net sales	143.5	159.1	426.7	461.4
Japan, Australia and New Zealand Segment \| Generics
Disaggregation of Revenue [Line Items]
Net sales	143.6	147.2	429.9	426.7
Emerging Markets Segment \| Brands
Disaggregation of Revenue [Line Items]
Net sales	436.2	424.1	1,324.6	1,242.7
Emerging Markets Segment \| Generics
Disaggregation of Revenue [Line Items]
Net sales	92.9	146.3	282.2	402.7
Operating Segment \| Developed Markets Segment
Disaggregation of Revenue [Line Items]
Net sales	2,215.9	2,255.6	6,430.4	6,266.6
Operating Segment \| Greater China
Disaggregation of Revenue [Line Items]
Net sales	702.6	615.2	2,096.5	1,759.6
Operating Segment \| Japan, Australia and New Zealand Segment
Disaggregation of Revenue [Line Items]
Net sales	287.1	306.3	856.6	888.1
Operating Segment \| Emerging Markets Segment
Disaggregation of Revenue [Line Items]
Net sales	$ 529.1	$ 570.4	$ 1,606.8	$ 1,645.4